Pevaryl 1% - skin emulsion - treatment of mycosis - 30 ml

Product Description

Antifungal for the local treatment of all fungal infections, including mixed infections caused by Gram-positive bacteria.

Therapeutic indications

The product is indicated in the treatment of:

- skin mycoses caused by dermatophytes, yeasts and molds; 
- skin infections caused by Gram-positive bacteria: streptococci and staphylococci; 
- mycotic otitis externa, mycosis of the ear canal (limited to the skin emulsion form); 
- onychomycosis; 
- Pityriasis Versicolor.

Composition

100 g of skin emulsion contain:

Active ingredient: econazole nitrate 1.0 g

Excipients: precipitated silica, mixture of stearic acid esters with glycols, mixture of fatty acids with polyethylene glycol, vaseline oil, butylhydroxyanisole, benzoic acid, perfume no. 4074, purified water. 

Contraindications

PEVARYL is contraindicated in patients with known hypersensitivity to the active ingredient or to any of the excipients.

Dosage and method of use

PEVARYL must be applied morning and evening, to the infected skin areas, with a light massage, until the mycosis has completely disappeared (1-3 weeks). It is recommended to continue applying PEVARYL for a few days after the mycosis has disappeared.

Intertriginous spaces (e.g., interdigital spaces of the foot, buttock folds) in the moist state should be cleaned with gauze before applying PEVARYL.
In the treatment of onychomycosis, an occlusive dressing is recommended.
In the treatment of otomycosis (only if there is no lesion of the eardrum), instill 1-2 drops of PEVARYL skin emulsion 1-2 times a day, or insert a strip of gauze soaked in it into the external auditory canal.

Regular use of PEVARYL as prescribed is of decisive importance for healing.

Warnings and precautions

All pharmaceutical forms of PEVARYL are indicated for external use only. PEVARYL is not for ophthalmic or oral use. If a sensitization or irritation reaction occurs, discontinue use of the product.

Interactions

Econazole is a known inhibitor of cytochromes CYP3A4 and CYP2C9. Despite limited systemic availability after cutaneous application, clinically relevant interactions may occur with other medicinal products, and some have been reported in patients treated with oral anticoagulants, such as warfarin and acenocoumarol. In patients treated with oral anticoagulants, caution should be exercised and the INR should be monitored more frequently. A dosage adjustment of the oral anticoagulant drug may be necessary during treatment with econazole and after its discontinuation.

Side effects

Like all medicines, PEVARYL can cause side effects, although not everybody gets them.
The most common side effects are: Common side effects reported are itching, burning sensation of the skin and pain.
Less commonly reported side effects are: erythema, malaise and swelling.
Furthermore, cases of angioedema, contact dermatitis, rash, urticaria, vesiculation, skin exfoliation and hypersensitivity have also been reported.
The use of topical products, especially if prolonged, can give rise to sensitization phenomena: if this occurs, suspend treatment and consult a doctor.
In case of particularly intense local reactions, it is necessary to suspend treatment and consult a doctor.

Format

30 ml bottle.